<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-27618" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Pregabalin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Cross</surname>
            <given-names>Aaron L.</given-names>
          </name>
          <aff>Jackson Memorial / University of Miami</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Viswanath</surname>
            <given-names>Omar</given-names>
          </name>
          <aff>Creighton University School of Medicine, Department of Anesthesiology, Omaha, NE</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sherman</surname>
            <given-names>Andrew L.</given-names>
          </name>
          <aff>Un of Miami Miller School of Med</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Aaron Cross declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Omar Viswanath declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Andrew Sherman declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>2</day>
          <month>5</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-27618.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Approved by the United States Food and Drug Administration (FDA) to address neuropathic pain linked to diabetic peripheral neuropathy, spinal cord injury, and postherpetic neuralgia, as well as fibromyalgia, pregabalin stands as adjunctive therapy for partial-onset seizures in adults with epilepsy. Off-label applications&#x000a0;include generalized anxiety disorder, social anxiety disorder, bipolar disorder, insomnia, and chronic pain conditions not sanctioned by the FDA. This activity prioritizes understanding pregabalin's mechanism of action, adverse event profile, and other pivotal factors such as off-label uses, dosing, monitoring, and pertinent interactions. The article&#x000a0;also discusses&#x000a0;the intricacies of administration, pharmacokinetics, and clinical toxicology, spotlighting the imperative role of the interprofessional healthcare team in overseeing pregabalin therapy.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of pregabalin.</p></list-item><list-item><p>Evaluate&#x000a0;the adverse effects of pregabalin.</p></list-item><list-item><p>Assess&#x000a0;the important dosage considerations of pregabalin.</p></list-item><list-item><p>Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from&#x000a0;pregabalin therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27618&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27618">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-27618.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Pregabalin was approved by the United States Food and Drug Administration (FDA) in 2004. Pregabalin is utilized for neuropathic pain and seizures.</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Neuropathic pain associated with spinal cord injury&#x000a0;<xref ref-type="bibr" rid="article-27618.r1">[1]</xref></p>
          </list-item>
          <list-item>
            <p>Neuropathic pain associated with diabetic peripheral neuropathy&#x000a0;<xref ref-type="bibr" rid="article-27618.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p>Neuropathic pain originating from postherpetic neuralgia&#x000a0;<xref ref-type="bibr" rid="article-27618.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>Adjunctive treatment for partial-onset seizures in adults with epilepsy&#x000a0;<xref ref-type="bibr" rid="article-27618.r4">[4]</xref></p>
          </list-item>
          <list-item>
            <p>Treatment of fibromyalgia&#x000a0;<xref ref-type="bibr" rid="article-27618.r5">[5]</xref></p>
          </list-item>
        </list>
        <p>European League Against Rheumatism (EULAR) guidelines note that pharmacological therapies should be considered for individuals experiencing severe pain or sleep disturbance. Pregabalin could be most appropriate when addressing both severe pain and sleep disturbance concurrently.<xref ref-type="bibr" rid="article-27618.r6">[6]</xref></p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Generalized anxiety disorder&#x000a0;<xref ref-type="bibr" rid="article-27618.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>Social anxiety disorder&#x000a0;<xref ref-type="bibr" rid="article-27618.r8">[8]</xref></p>
          </list-item>
          <list-item>
            <p>Insomnia&#x000a0;<xref ref-type="bibr" rid="article-27618.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p>Chronic pain conditions&#x000a0;<xref ref-type="bibr" rid="article-27618.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p>Uremic pruritus&#x000a0;<xref ref-type="bibr" rid="article-27618.r11">[11]</xref><xref ref-type="bibr" rid="article-27618.r12">[12]</xref></p>
          </list-item>
          <list-item>
            <p>Chronic cough&#x000a0;<xref ref-type="bibr" rid="article-27618.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p>Restless leg syndrome&#x000a0;<xref ref-type="bibr" rid="article-27618.r14">[14]</xref><xref ref-type="bibr" rid="article-27618.r15">[15]</xref></p>
          </list-item>
          <list-item>
            <p>Complex regional pain syndrome&#x000a0;<xref ref-type="bibr" rid="article-27618.r16">[16]</xref></p>
          </list-item>
          <list-item>
            <p>Prophylaxis of migraine&#x000a0;<xref ref-type="bibr" rid="article-27618.r17">[17]</xref></p>
          </list-item>
          <list-item>
            <p>Trigeminal neuralgia&#x000a0;<xref ref-type="bibr" rid="article-27618.r18">[18]</xref></p>
          </list-item>
        </list>
        <p>There is significant controversy regarding the efficacy of pregabalin for the off-label indications. Therefore, clinicians should carefully monitor patients for therapeutic success while monitoring adverse drug reactions.</p>
      </sec>
      <sec id="article-27618.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Pregabalin is structurally analogous to the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). Pregabalin has been altered as a lipophilic formulation to enhance diffusion across the blood-brain barrier. However, the drug does not directly bind to GABA-A or GABA-B receptors. In preclinical studies, pregabalin binds to presynaptic voltage-gated calcium channels (VGCC) at the &#x003b1;-2-&#x003b4; subunit in the central nervous system. The binding of the &#x003b1;-2-&#x003b4; subunit reduces the depolarization-induced calcium influx into neurons and decreases the release of excitatory neurotransmitters. This action may account for the analgesic and anticonvulsant effects of pregabalin. Pregabalin has no known activity at serotonin, opiate sodium channels, or receptors and does not modify cyclooxygenase activity.<xref ref-type="bibr" rid="article-27618.r19">[19]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> Pregabalin is absorbed in the small intestine and proximal colon in a linear and dose-proportional fashion. However, differences&#x000a0;have been noted between pregabalin controlled-release and immediate-release formulations. Pregabalin controlled release (CR) achieves peak plasma concentrations within 8.0 hours (range: 5.0&#x02013;12.0), contrasting with the more rapid attainment of peak concentration seen with immediate-release pregabalin, typically occurring at 0.7 hours (range: 0.7&#x02013;1.5).&#x000a0;</p>
        <p><bold>Distribution:</bold> Pregabalin's apparent volume of distribution is approximately 0.5 L/kg. Pregabalin does not bind to plasma proteins.<xref ref-type="bibr" rid="article-27618.r20">[20]</xref>&#x000a0;Pregabalin readily crosses the blood-brain barrier.</p>
        <p><bold>Metabolism:</bold> Pregabalin does not induce or inhibit liver enzymes such as the cytochrome P450 system.<xref ref-type="bibr" rid="article-27618.r21">[21]</xref></p>
        <p><bold>Excretion:</bold> Pregabalin is primarily eliminated from the systemic circulation via renal excretion as an unchanged drug. In normal renal function, the mean elimination half-life of pregabalin is 6.3 hours. Pregabalin elimination is closely linked to creatinine clearance and is approximately proportional to creatinine clearance.</p>
      </sec>
      <sec id="article-27618.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths&#x000a0;</bold>
</p>
        <p>Pregabalin is offered in capsule form in strengths ranging from 25 to 300 mg, including 25, 50, 75, 100, 150, 200, 225, and 300 mg. Additionally, it is available as an oral solution at a concentration of 20 mg/mL. Extended-release tablets are also available in strengths of 82.5 mg, 165 mg, and 330 mg. Researchers have examined pregabalin at dosages up to 600 mg/d. However, they did not find 600 mg daily to provide significant additional benefit, and it was less well tolerated due to adverse effects. When discontinuing pregabalin, the recommendation is to taper the drug gradually over&#x000a0;1 week. In patients with seizure disorders, pregabalin should be withdrawn gradually to minimize the risk of increased seizure.</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Management of neuropathic pain associated</bold>&#x000a0;<bold>with</bold>&#x000a0;<bold>diabetic peripheral neuropathy:&#x000a0;</bold>The recommended maximum therapeutic dosage is 300 mg/d. The suggested starting dosage is 50 mg&#x000a0;3 times daily. The dosage can increase to 300 mg/d within&#x000a0;1 week of starting treatment.<xref ref-type="bibr" rid="article-27618.r22">[22]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Management of neuropathic pain associated with spinal cord injury:&#x000a0;</bold>The recommended therapeutic dosage is 150 mg to 600 mg daily. The recommended starting dosage is 75 mg twice daily. The dosage may be increased to 150 mg twice daily within&#x000a0;1 week of initiating treatment. Patients with suboptimal pain relief following 2 to 3 weeks of treatment with 150 mg twice daily may be increased up to 300 mg twice daily. In spinal cord injury, pain improvement can be seen as early as&#x000a0;1 week after initiating treatment. However, to evaluate the efficacy of pregabalin, it is recommended that the medication be tried for 4 to 6 weeks if the patient tolerates it.<xref ref-type="bibr" rid="article-27618.r23">[23]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Management of postherpetic neuralgia:&#x000a0;</bold>The recommended therapeutic dosage is 150 mg to 300 mg daily, divided into dosing twice or thrice daily. The recommended starting dosage is 75 mg&#x000a0;twice&#x000a0;daily or 50 mg thrice daily. The&#x000a0;dosage can be increased to 300 mg daily within&#x000a0;1 week of starting treatment. After 2 to 4 weeks of treatment with 300 mg daily, patients with suboptimal pain relief can be increased to 600 mg, divided into twice daily or thrice daily.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Management of fibromyalgia:&#x000a0;</bold>The recommended therapeutic dosage is 300 mg to 450 mg daily. The recommended initial dosage is 150 mg/d, divided into twice-daily doses. The&#x000a0;dosage can be increased to 300 mg daily within&#x000a0;1 week of starting treatment. Patients with suboptimal pain relief on 300 mg daily may further increase to 450 mg daily, divided into twice-daily dosing.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Adjunctive therapy for adults with partial onset seizures:&#x000a0;</bold>Pregabalin is FDA-approved only as an adjunctive for treating partial-onset seizures. The effective dosage is 150 mg to 600 mg daily, divided twice or thrice-daily dosing. The suggested starting dosage is no greater than 150 mg daily, and the total dosage can increase to 600 mg daily.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Cough and chronic refractory:&#x000a0;</bold>Pregabalin is off-label used in cough and chronic refractory conditions. The initial dosage is 75 mg daily, which may increase by 75 mg during the first week of treatment. The maximum dosage can be up to 300 mg daily, divided thrice per dosing.<xref ref-type="bibr" rid="article-27618.r24">[24]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Generalized anxiety disorder:&#x000a0;</bold>Pregabalin is also off-label used in generalized anxiety disorder. The initial dosage is 75 mg daily, which may increase by 75 mg during the first week of treatment. The maximum dosage can be up to 300 mg thrice daily.<xref ref-type="bibr" rid="article-27618.r25">[25]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Chronic pruritus:&#x000a0;</bold>Pregabalin is also off-label and used as a preferred treatment in patients with pruritus resistance. The initial dosage is 75 mg twice daily, which may increase by 150 mg to 300 mg twice or thrice daily. The&#x000a0;dosage of pregabalin can be increased up to 600 mg daily in oncology patient populations.<xref ref-type="bibr" rid="article-27618.r26">[26]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Restless legs syndrome:&#x000a0;</bold>Another off-label use of pregabalin is restless legs syndrome. The initial&#x000a0;dosage is 50 to 75 mg daily before bedtime, which may increase by 75 to 150 mg weekly. The usual therapeutic&#x000a0;dosage&#x000a0;is up to 150 mg to 450 mg daily, based on the effectiveness and tolerability of therapy.<xref ref-type="bibr" rid="article-27618.r27">[27]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Social anxiety disorder:&#x000a0;</bold>Pregabalin is off-label used as mono or adjuvant therapy in social anxiety disorder, cough, and chronic refractory conditions. The initial&#x000a0;dosage&#x000a0;is 100 mg thrice daily, which may increase by 150 mg daily over&#x000a0;1 week. This&#x000a0;dosage may increase to 600 mg daily based on response and tolerability.<xref ref-type="bibr" rid="article-27618.r28">[28]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Specific Patient Population</bold>
</p>
        <p><bold>Renal impairment:&#x000a0;</bold>Pregabalin is primarily eliminated by renal excretion. Adjust the pregabalin dose in patients with impaired renal function. According to prescription drug manufacturers, the following are recommendations on dose reductions for patients with reduced creatinine clearance and those undergoing hemodialysis.</p>
        <list list-type="bullet">
          <list-item>
            <p>CrCl &#x02265;60 mL/min: no dose modification is recommended</p>
          </list-item>
          <list-item>
            <p>CrCl 30 to 60 mL/min: 50% dose of recommended daily dose</p>
          </list-item>
          <list-item>
            <p>CrCl 15 to 30 mL/min: 25% dose of recommended daily dose</p>
          </list-item>
          <list-item>
            <p>CrCl &#x02264;15 mL/min: 16% to 8% dose of recommended daily dose</p>
          </list-item>
        </list>
        <p>A supplementary dosage of approximately an additional 25 mg of the recommended daily dose following hemodialysis is recommended.</p>
        <p><bold>Hepatic impairment:</bold>&#x000a0;Although not explicitly studied, because pregabalin is not protein-bound, it is unlikely that patients with hepatic impairment require dosing modifications.</p>
        <p><bold>Pregnancy considerations:</bold>&#x000a0;Clinicians should help enroll pregnant patients in the North American Antiepileptic Drug (NAAED) Pregnancy Registry to observe pregnancy outcomes in women exposed to pregabalin during pregnancy and provide information on the effects of in-utero exposure to pregabalin.</p>
        <p><bold>Breastfeeding considerations:&#x000a0;</bold>Because the potential risk outweighs the benefits, breastfeeding or pregabalin should be stopped, especially while nursing newborns or infants.<xref ref-type="bibr" rid="article-27618.r29">[29]</xref></p>
        <p><bold>Older patients:</bold>&#x000a0;Pregabalin is mainly cleared through the kidneys, putting older patients at higher risk of adverse reactions due to a potential decline in renal function. Therefore, careful dosage selection and regular monitoring of renal function are crucial in this population. According to the AGS beers criteria (2023), reduce the pregabalin dosage if creatinine clearance is less than 60 mL/min.<xref ref-type="bibr" rid="article-27618.r30">[30]</xref></p>
        <p><bold>Pediatric patients:</bold>&#x000a0;The effectiveness of pregabalin in pediatric patients with focal onset seizures was demonstrated in a study, showing greater seizure reduction compared to placebo in patients who are 1 month to&#x000a0;younger than 4 years.<xref ref-type="bibr" rid="article-27618.r31">[31]</xref></p>
      </sec>
      <sec id="article-27618.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Most reported adverse effects caused by pregabalin were mild to moderate intensity, dose-dependent, and occurred within the first&#x000a0;2 weeks of initiating treatment.</p>
        <list list-type="bullet">
          <list-item>
            <p>The most common adverse events were those affecting the central nervous system (CNS). Somnolence and dizziness occurred most frequently and were the most common adverse reactions that led to the discontinuation of pregabalin.<xref ref-type="bibr" rid="article-27618.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p>The most common adverse reactions reported in premarketing trials for pregabalin, occurring in over 5% of patients and twice the rate compared to placebo, include somnolence, dizziness, blurred vision, difficulty with concentration/attention, dry mouth, edema, and weight gain.<xref ref-type="bibr" rid="article-27618.r32">[32]</xref><xref ref-type="bibr" rid="article-27618.r33">[33]</xref></p>
          </list-item>
          <list-item>
            <p>Weight gain associated with pregabalin is dose-dependent and occurs in up to 14% of patients receiving 600 mg daily.</p>
          </list-item>
          <list-item>
            <p>Following rapid or abrupt discontinuation of pregabalin, some patients reported insomnia, nausea, headache, anxiety, nervousness, irritability, hyperhidrosis, and diarrhea.<xref ref-type="bibr" rid="article-27618.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p>Chronic use of pregabalin can result in physical dependence, and there is a risk of abuse associated with its use, especially in patients on opioid medicines or who have a history of substance abuse.<xref ref-type="bibr" rid="article-27618.r34">[34]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Pregabalin's pharmacokinetics are unlikely to be affected by other agents due to its predominant renal excretion, minimal metabolism, and lack of plasma protein binding. Studies suggest no significant pharmacokinetic interactions between pregabalin and common antiepileptic drugs. Regarding pharmacodynamics, no pharmacokinetic interactions were observed.</p>
          </list-item>
          <list-item>
            <p>Coadministration of pregabalin with CNS depressants such as opioids, benzodiazepines, or ethanol is synergistic and should be avoided.<xref ref-type="bibr" rid="article-27618.r35">[35]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27618.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Pregabalin is contraindicated in patients with a known hypersensitivity to pregabalin. Hypersensitivity reactions, including angioedema, have been reported.<xref ref-type="bibr" rid="article-27618.r36">[36]</xref></p>
        <p>
<bold>Warning and Precautions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Pregabalin may cause fetal harm. Counsel patients that there is a potential risk to the fetus.<xref ref-type="bibr" rid="article-27618.r37">[37]</xref></p>
          </list-item>
          <list-item>
            <p>Pregabalin has been detected in breast milk; breastfeeding is not advisable, and an alternative medication is preferred.<xref ref-type="bibr" rid="article-27618.r29">[29]</xref></p>
          </list-item>
          <list-item>
            <p>An analysis of the FAERS (FDA Adverse Event Reporting System) database reveals that pregabalin has been associated with rhabdomyolysis. Patients should report any unexplained muscle symptoms promptly, and treatment should be discontinued if myopathy is suspected or creatine kinase levels are markedly elevated.<xref ref-type="bibr" rid="article-27618.r38">[38]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27618.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Key facts to keep in mind when monitoring:</p>
        <list list-type="bullet">
          <list-item>
            <p>Antiepileptic drugs such as pregabalin may increase the risk of suicidal thoughts or behavior.<xref ref-type="bibr" rid="article-27618.r39">[39]</xref>&#x000a0;Patients under treatment with pregabalin should be monitored for symptoms of suicidal ideation or behavior, new or worsening depression, and other changes in behavior or mood.</p>
          </list-item>
          <list-item>
            <p>Patients should be monitored for weight gain, edema, respiratory rate, and other adverse events, which could result in issues with treatment adherence with pregabalin.</p>
          </list-item>
          <list-item>
            <p>Therapeutic success should be evaluated by periodic evaluation of disease and potential adverse effects.</p>
          </list-item>
          <list-item>
            <p>Prescribing cascades, notably involving pregabalin or gabapentin, contribute to polypharmacy in older adults and should be monitored. A study found a significant link between initiating pregabalin or gabapentin and subsequent loop diuretic use, indicating a prescribing cascade.<xref ref-type="bibr" rid="article-27618.r40">[40]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27618.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>There is limited information regarding overdose with pregabalin. The highest known accidental overdose of pregabalin during clinical development was 8000 mg; this event was without significant clinical consequences. The most commonly reported adverse events with overdose were reduced consciousness, confusional state, agitation, depression/anxiety, and restlessness in the postmarketing studies. In addition, heart block, seizures, and death have also been reported in some patients taking combination with other CNS depressants.<xref ref-type="bibr" rid="article-27618.r41">[41]</xref></p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>There is no specific antidote for overdose with pregabalin. If required, unabsorbed pregabalin can be eliminated by gastric lavage or emesis. General supportive care should be provided to the patient. Maintain the airway and monitor the patient's vital signs and clinical status. A Certified Poison Control Center (800-222-1222) should be contacted for the latest information on the management of overdose with pregabalin. Pregabalin can be removed by standard hemodialysis procedures, resulting in approximately 50% clearance of pregabalin in 4 hours.</p>
        <p>
<bold>Recommendations</bold>
</p>
        <p>The Extracorporeal Treatments in Poisoning (EXTRIP) suggests against performing extracorporeal treatment (ECTR) in addition to standard care alone for pregabalin/gabapentin poisoning in normal kidney function. However, if decreased kidney function and coma requiring mechanical ventilation are present, the workgroup suggests performing extracorporeal treatment in addition to standard care (weak recommendation, very low quality of evidence).<xref ref-type="bibr" rid="article-27618.r42">[42]</xref></p>
      </sec>
      <sec id="article-27618.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Pregabalin is commonly used to manage pain disorders and as adjunctive treatment for partial-onset seizures. While the drug is relatively safe, physicians, pharmacists, nurse practitioners, and physician assistants must regularly monitor the patient. Pregabalin is known to cause depression and suicidal thoughts, so a mental assessment is advisable at each visit. Pregabalin should not be prescribed for musculoskeletal pain. Patients should be educated about the other adverse effects and told not to drive when taking the drug or combine it with other antiseizure medications or alcohol. Pharmacists should perform medication reconciliation and watch for potential drug interactions. Nurses should verify the dose before administering and report any concerns to clinicians. Before altering the treatment plan, consultation with a neurologist, psychiatrist, or pain management specialist is beneficial.<xref ref-type="bibr" rid="article-27618.r5">[5]</xref>&#x000a0;The collaborative approach of all interprofessional healthcare team members can result in higher treatment success and improve patient outcomes with pregabalin therapy.</p>
      </sec>
      <sec id="article-27618.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27618&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27618">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/27618/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=27618">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-27618.s11">
        <title>References</title>
        <ref id="article-27618.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tong</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhengyao</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Mei</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dongpo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Qian</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fengqun</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Pregabalin and Gabapentin in Patients with Spinal Cord Injury-Related Neuropathic Pain: A Network Meta-Analysis.</article-title>
            <source>Pain Ther</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>1497</fpage>
            <page-range>1497-1509</page-range>
            <pub-id pub-id-type="pmid">34491542</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27618.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bragg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Marrison</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Haley</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Diabetic Peripheral Neuropathy: Prevention and Treatment.</article-title>
            <source>Am Fam Physician</source>
            <year>2024</year>
            <month>Mar</month>
            <volume>109</volume>
            <issue>3</issue>
            <fpage>226</fpage>
            <page-range>226-232</page-range>
            <pub-id pub-id-type="pmid">38574212</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27618.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Argoff</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>Review of current guidelines on the care of postherpetic neuralgia.</article-title>
            <source>Postgrad Med</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>123</volume>
            <issue>5</issue>
            <fpage>134</fpage>
            <page-range>134-42</page-range>
            <pub-id pub-id-type="pmid">21904096</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27618.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>French</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kwan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fakhoury</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pitman</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>DuBrava</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Knapp</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yurkewicz</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Pregabalin monotherapy in patients with partial-onset seizures: a historical-controlled trial.</article-title>
            <source>Neurology</source>
            <year>2014</year>
            <month>Feb</month>
            <day>18</day>
            <volume>82</volume>
            <issue>7</issue>
            <fpage>590</fpage>
            <page-range>590-7</page-range>
            <pub-id pub-id-type="pmid">24415567</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27618.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bidari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Moazen-Zadeh</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ghavidel-Parsa</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rahmani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hosseini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hassankhani</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Comparing duloxetine and pregabalin for treatment of pain and depression in women with fibromyalgia: an open-label randomized clinical trial.</article-title>
            <source>Daru</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>27</volume>
            <issue>1</issue>
            <fpage>149</fpage>
            <page-range>149-158</page-range>
            <pub-id pub-id-type="pmid">30877484</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27618.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Macfarlane</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Kronisch</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dean</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Atzeni</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>H&#x000e4;user</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Flu&#x000df;</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Choy</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kosek</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Amris</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Branco</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dincer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Leino-Arjas</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Longley</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>McCarthy</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Makri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Perrot</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sarzi-Puttini</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>GT</given-names>
              </name>
            </person-group>
            <article-title>EULAR revised recommendations for the management of fibromyalgia.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>76</volume>
            <issue>2</issue>
            <fpage>318</fpage>
            <page-range>318-328</page-range>
            <pub-id pub-id-type="pmid">27377815</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27618.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hong</surname>
                <given-names>JSW</given-names>
              </name>
              <name>
                <surname>Atkinson</surname>
                <given-names>LZ</given-names>
              </name>
              <name>
                <surname>Al-Juffali</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Awad</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Geddes</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Tunbridge</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Harrison</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Cipriani</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Gabapentin and pregabalin in bipolar disorder, anxiety states, and insomnia: Systematic review, meta-analysis, and rationale.</article-title>
            <source>Mol Psychiatry</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>27</volume>
            <issue>3</issue>
            <fpage>1339</fpage>
            <page-range>1339-1349</page-range>
            <pub-id pub-id-type="pmid">34819636</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27618.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kawalec</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cierniak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pilc</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nowak</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Pregabalin for the treatment of social anxiety disorder.</article-title>
            <source>Expert Opin Investig Drugs</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>24</volume>
            <issue>4</issue>
            <fpage>585</fpage>
            <page-range>585-94</page-range>
            <pub-id pub-id-type="pmid">25361817</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27618.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Di Iorio</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Matarazzo</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Di Tizio</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Martinotti</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Treatment-resistant insomnia treated with pregabalin.</article-title>
            <source>Eur Rev Med Pharmacol Sci</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>17</volume>
            <issue>11</issue>
            <fpage>1552</fpage>
            <page-range>1552-4</page-range>
            <pub-id pub-id-type="pmid">23771546</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27618.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Derry</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Straube</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wiffen</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Aldington</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Pregabalin for neuropathic pain in adults.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2019</year>
            <month>Jan</month>
            <day>23</day>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>CD007076</fpage>
            <pub-id pub-id-type="pmid">30673120</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27618.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boehlke</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Joos</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Coune</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Meerpohl</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Buroh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hercz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Schwarzer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological interventions for pruritus in adult palliative care patients.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2023</year>
            <month>Apr</month>
            <day>14</day>
            <volume>4</volume>
            <issue>2023</issue>
            <fpage>CD008320</fpage>
            <pub-id pub-id-type="pmid">37314034</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27618.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Santos-Alonso</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Maldonado Mart&#x000ed;n</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>S&#x000e1;nchez Villanueva</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>&#x000c1;lvarez Garc&#x000ed;a</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Vaca Gallardo</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Bajo Rubio</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Del Peso Gilsanz</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ossorio Gonz&#x000e1;lez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Selgas Guti&#x000e9;rrez</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Pruritus in dialysis patients. Review and new perspectives.</article-title>
            <source>Nefrologia (Engl Ed)</source>
            <year>2022</year>
            <season>Jan-Feb</season>
            <volume>42</volume>
            <issue>1</issue>
            <fpage>15</fpage>
            <page-range>15-21</page-range>
            <pub-id pub-id-type="pmid">36153894</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27618.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adeli</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Beigi</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Ahmadpour</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Habibi</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Pashaei</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Sharifipour</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Shakeri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Asghari</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Effects of Pregabalin as a Neural Pathway Inhibitor for the Treatment of Resistant Subacute and Chronic Cough: A Pilot Clinical Trials Study.</article-title>
            <source>Rev Recent Clin Trials</source>
            <year>2023</year>
            <volume>18</volume>
            <issue>4</issue>
            <fpage>269</fpage>
            <page-range>269-274</page-range>
            <pub-id pub-id-type="pmid">37888808</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27618.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bae</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>YW</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Earley</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>The Safety and Efficacy of Pregabalin Add-on Therapy in Restless Legs Syndrome Patients.</article-title>
            <source>Front Neurol</source>
            <year>2021</year>
            <volume>12</volume>
            <fpage>786408</fpage>
            <pub-id pub-id-type="pmid">34912291</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27618.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pellitteri</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Versace</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Merlino</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nilo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gigli</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Valente</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>A comprehensive update on the ADMET considerations for &#x003b1;2&#x003b4; calcium channel ligand medications for treating restless legs syndrome.</article-title>
            <source>Expert Opin Drug Metab Toxicol</source>
            <year>2024</year>
            <month>Mar</month>
            <volume>20</volume>
            <issue>3</issue>
            <fpage>133</fpage>
            <page-range>133-142</page-range>
            <pub-id pub-id-type="pmid">38482850</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27618.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harden</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>McCabe</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Goebel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Massey</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Suvar</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Grieve</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bruehl</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Complex Regional Pain Syndrome: Practical Diagnostic and Treatment Guidelines, 5th Edition.</article-title>
            <source>Pain Med</source>
            <year>2022</year>
            <month>Jun</month>
            <day>10</day>
            <volume>23</volume>
            <issue>Suppl 1</issue>
            <fpage>S1</fpage>
            <page-range>S1-S53</page-range>
            <pub-id pub-id-type="pmid">35687369</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27618.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parikh</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Silberstein</surname>
                <given-names>SD</given-names>
              </name>
            </person-group>
            <article-title>Current Status of Antiepileptic Drugs as Preventive Migraine Therapy.</article-title>
            <source>Curr Treat Options Neurol</source>
            <year>2019</year>
            <month>Mar</month>
            <day>18</day>
            <volume>21</volume>
            <issue>4</issue>
            <fpage>16</fpage>
            <pub-id pub-id-type="pmid">30880369</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27618.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bendtsen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zakrzewska</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Abbott</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Braschinsky</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Di Stefano</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Donnet</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Eide</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Leal</surname>
                <given-names>PRL</given-names>
              </name>
              <name>
                <surname>Maarbjerg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>May</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nurmikko</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Obermann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Cruccu</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>European Academy of Neurology guideline on trigeminal neuralgia.</article-title>
            <source>Eur J Neurol</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>26</volume>
            <issue>6</issue>
            <fpage>831</fpage>
            <page-range>831-849</page-range>
            <pub-id pub-id-type="pmid">30860637</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27618.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taylor</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Angelotti</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fauman</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery.</article-title>
            <source>Epilepsy Res</source>
            <year>2007</year>
            <month>Feb</month>
            <volume>73</volume>
            <issue>2</issue>
            <fpage>137</fpage>
            <page-range>137-50</page-range>
            <pub-id pub-id-type="pmid">17126531</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27618.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ben-Menachem</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Pregabalin pharmacology and its relevance to clinical practice.</article-title>
            <source>Epilepsia</source>
            <year>2004</year>
            <volume>45 Suppl 6</volume>
            <fpage>13</fpage>
            <page-range>13-8</page-range>
            <pub-id pub-id-type="pmid">15315511</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27618.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Keller</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Bassan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Amberg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Burns Naas</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Chambers</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cross</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jahnke</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Luniwal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Manganelli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mestres</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mihalchik-Burhans</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Woolley</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tice</surname>
                <given-names>RR</given-names>
              </name>
            </person-group>
            <article-title><italic>In silico</italic> approaches in carcinogenicity hazard assessment: case study of pregabalin, a nongenotoxic mouse carcinogen.</article-title>
            <source>Front Toxicol</source>
            <year>2023</year>
            <volume>5</volume>
            <fpage>1234498</fpage>
            <pub-id pub-id-type="pmid">38026843</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27618.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moulin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Boulanger</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Clarke</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Dao</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Finley</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Furlan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gilron</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Morley-Forster</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Sessle</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Squire</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Stinson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Taenzer</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Velly</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ware</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Weinberg</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Williamson</surname>
                <given-names>OD</given-names>
              </name>
              <collab>Canadian Pain Society</collab>
            </person-group>
            <article-title>Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society.</article-title>
            <source>Pain Res Manag</source>
            <year>2014</year>
            <season>Nov-Dec</season>
            <volume>19</volume>
            <issue>6</issue>
            <fpage>328</fpage>
            <page-range>328-35</page-range>
            <pub-id pub-id-type="pmid">25479151</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27618.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davari</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Amani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Amani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Khanijahani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Akbarzadeh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shabestan</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Pregabalin and gabapentin in neuropathic pain management after spinal cord injury: a systematic review and meta-analysis.</article-title>
            <source>Korean J Pain</source>
            <year>2020</year>
            <month>Jan</month>
            <day>01</day>
            <volume>33</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-12</page-range>
            <pub-id pub-id-type="pmid">31888312</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27618.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vertigan</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Kapela</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Birring</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>McElduff</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>PG</given-names>
              </name>
            </person-group>
            <article-title>Pregabalin and Speech Pathology Combination Therapy for Refractory Chronic Cough: A Randomized Controlled Trial.</article-title>
            <source>Chest</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>149</volume>
            <issue>3</issue>
            <fpage>639</fpage>
            <page-range>639-48</page-range>
            <pub-id pub-id-type="pmid">26447687</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27618.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baldwin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Woods</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lawson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis.</article-title>
            <source>BMJ</source>
            <year>2011</year>
            <month>Mar</month>
            <day>11</day>
            <volume>342</volume>
            <fpage>d1199</fpage>
            <pub-id pub-id-type="pmid">21398351</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27618.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>At&#x00131;&#x0015f;</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bilir Kaya</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Pregabalin treatment of three cases with brachioradial pruritus.</article-title>
            <source>Dermatol Ther</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>30</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">28168835</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27618.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Allen</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Garcia-Borreguero</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Polo</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>DuBrava</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Miceli</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Knapp</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Winkelman</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Comparison of pregabalin with pramipexole for restless legs syndrome.</article-title>
            <source>N Engl J Med</source>
            <year>2014</year>
            <month>Feb</month>
            <day>13</day>
            <volume>370</volume>
            <issue>7</issue>
            <fpage>621</fpage>
            <page-range>621-31</page-range>
            <pub-id pub-id-type="pmid">24521108</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27618.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feltner</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Liu-Dumaw</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schweizer</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bielski</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study.</article-title>
            <source>Int Clin Psychopharmacol</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>26</volume>
            <issue>4</issue>
            <fpage>213</fpage>
            <page-range>213-20</page-range>
            <pub-id pub-id-type="pmid">21368587</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27618.r29">
          <label>29</label>
          <element-citation publication-type="book">
            <chapter-title>Pregabalin</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000881</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27618.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <collab>By the 2023 American Geriatrics Society Beers Criteria&#x000ae; Update Expert Panel</collab>
            <article-title>American Geriatrics Society 2023 updated AGS Beers Criteria&#x000ae; for potentially inappropriate medication use in older adults.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>2023</year>
            <month>Jul</month>
            <volume>71</volume>
            <issue>7</issue>
            <fpage>2052</fpage>
            <page-range>2052-2081</page-range>
            <pub-id pub-id-type="pmid">37139824</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27618.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mann</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Antinew</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Knapp</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Almas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Scavone</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Modequillo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Makedonska</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ortiz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kyrychenko</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nordli</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Farkas</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Farkas</surname>
                <given-names>MK</given-names>
              </name>
              <collab>A0081042 study group</collab>
            </person-group>
            <article-title>Pregabalin adjunctive therapy for focal onset seizures in children 1 month to &#x0003c;4 years of age: A double-blind, placebo-controlled, video-electroencephalographic trial.</article-title>
            <source>Epilepsia</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>61</volume>
            <issue>4</issue>
            <fpage>617</fpage>
            <page-range>617-626</page-range>
            <pub-id pub-id-type="pmid">32189338</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27618.r32">
          <label>32</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Preuss</surname>
                <given-names>CV</given-names>
              </name>
              <name>
                <surname>Kalava</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>KC</given-names>
              </name>
            </person-group>
            <chapter-title>Prescription of Controlled Substances: Benefits and Risks</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>4</month>
            <day>29</day>
            <pub-id pub-id-type="pmid">30726003</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27618.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <article-title>Drugs for chronic insomnia.</article-title>
            <source>Med Lett Drugs Ther</source>
            <year>2018</year>
            <month>Dec</month>
            <day>17</day>
            <volume>60</volume>
            <issue>1562</issue>
            <fpage>201</fpage>
            <page-range>201-205</page-range>
            <pub-id pub-id-type="pmid">30625122</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27618.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chalabianloo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Schj&#x000f8;tt</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>[Pregabalin and its potential for abuse].</article-title>
            <source>Tidsskr Nor Laegeforen</source>
            <year>2009</year>
            <month>Jan</month>
            <day>29</day>
            <volume>129</volume>
            <issue>3</issue>
            <fpage>186</fpage>
            <page-range>186-7</page-range>
            <pub-id pub-id-type="pmid">19180163</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27618.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lo-Ciganic</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Winterstein</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Tighe</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>YJ</given-names>
              </name>
            </person-group>
            <article-title>Concurrent Use of Prescription Opioids and Gabapentinoids in Older Adults.</article-title>
            <source>Am J Prev Med</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>62</volume>
            <issue>4</issue>
            <fpage>519</fpage>
            <page-range>519-528</page-range>
            <pub-id pub-id-type="pmid">34802816</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27618.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ortega-Camarero</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Avila</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Prados Casta&#x000f1;o</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pi&#x000f1;ero</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Quiralte</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cimbollek</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Challenge-based pregabalin induced urticaria and angioedema. A case report.</article-title>
            <source>Allergol Immunopathol (Madr)</source>
            <year>2012</year>
            <season>Sep-Oct</season>
            <volume>40</volume>
            <issue>5</issue>
            <fpage>323</fpage>
            <pub-id pub-id-type="pmid">22266144</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27618.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andrade</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Safety of Pregabalin in Pregnancy.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2018</year>
            <month>Oct</month>
            <day>02</day>
            <volume>79</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">30289631</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27618.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Deng</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Rhabdomyolysis associated with newer-generation anti-seizure medications (ASMs): a real-world retrospective and pharmacovigilance study.</article-title>
            <source>Front Pharmacol</source>
            <year>2023</year>
            <volume>14</volume>
            <fpage>1197470</fpage>
            <pub-id pub-id-type="pmid">37849732</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27618.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abrahamsson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Berge</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>&#x000d6;jehagen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>H&#x000e5;kansson</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment-A nation-wide register-based open cohort study.</article-title>
            <source>Drug Alcohol Depend</source>
            <year>2017</year>
            <month>May</month>
            <day>01</day>
            <volume>174</volume>
            <fpage>58</fpage>
            <page-range>58-64</page-range>
            <pub-id pub-id-type="pmid">28315808</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27618.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Growdon</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Jing</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Deardorff</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Boscardin</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Byers</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Boockvar</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Steinman</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Which older adults are at highest risk of prescribing cascades? A national study of the gabapentinoid-loop diuretic cascade.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>2024</year>
            <month>Jun</month>
            <volume>72</volume>
            <issue>6</issue>
            <fpage>1728</fpage>
            <page-range>1728-1740</page-range>
            <pub-id pub-id-type="pmid">38547357</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27618.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Evoy</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Morrison</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Saklad</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Abuse and Misuse of Pregabalin and Gabapentin.</article-title>
            <source>Drugs</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>77</volume>
            <issue>4</issue>
            <fpage>403</fpage>
            <page-range>403-426</page-range>
            <pub-id pub-id-type="pmid">28144823</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27618.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bouchard</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yates</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Calello</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Gosselin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Lavergne</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Ostermann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ghannoum</surname>
                <given-names>M</given-names>
              </name>
              <collab>EXTRIP Workgroup</collab>
            </person-group>
            <article-title>Extracorporeal Treatment for Gabapentin and Pregabalin Poisoning: Systematic Review and Recommendations From the EXTRIP Workgroup.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>79</volume>
            <issue>1</issue>
            <fpage>88</fpage>
            <page-range>88-104</page-range>
            <pub-id pub-id-type="pmid">34799138</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
